查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2110258

全球疫苗佐劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Vaccine Adjuvants Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 270 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球疫苗佐劑市場預計將從2025年的43億美元成長至2034年的70.9億美元，2026年至2034年的複合年成長率（CAGR）為5.72%。全球疫苗佐劑市場正穩步成長，這主要得益於疫苗研發活動的活性化以及需要增強免疫刺激的重組疫苗和次單位疫苗的日益普及。市場需求依然強勁，這得益於免疫接種計劃的擴展和應對感染疾病疫情準備工作的加強。此外，生物製藥領域的合作以及公共衛生領域的資助舉措正在加速新型佐劑平台的創新，有助於擴大商業機會並推動全球市場的持續成長。

關鍵促進因素包括：老年人和免疫力缺乏患者對疫苗效力的需求不斷提高；奈米顆粒和基於Toll樣受體（TLR）的佐劑技術不斷進步；以及監管機構對先進疫苗製劑的支持力度加大。應對疫情和治療性疫苗投入的增加進一步推高了需求。此外，安全性的提高和免疫反應持久性的增強也促使佐劑在預防性和治療性疫苗研發管線中得到更廣泛的應用。

由於製造商專注於複雜佐劑和精準的免疫調節策略，市場前景依然強勁。癌症疫苗、個人化免疫平台以及新興市場的拓展將創造更多收入來源。大規模生產技術的進步和對免疫機制更深入的理解將加速商業化進程，預計市場將走上長期永續成長的道路。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球疫苗佐劑市場：按類型分類

  • 市場分析、洞察與預測
  • 病原
  • 佐劑乳劑
  • 顆粒物
  • 組合
  • 其他

第5章：全球疫苗佐劑市場：依應用領域分類

  • 市場分析、洞察與預測
  • 感染疾病
  • 癌症
  • 其他

第6章：全球疫苗佐劑市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 皮內給藥
  • 鼻內給藥
  • 肌肉內部
  • 其他

第7章 全球疫苗佐劑市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Adjuvance Technologies Inc
    • Agenus Inc
    • Allergy Therapeutics Plc
    • Aurorium
    • CaPtivate Pharmaceuticals LLC
    • Creative Diagnostics
    • Croda International Plc（Brenntag Biosector）
    • CSL Limited
    • Dynavax Technologies Corporation
    • EuBiologics Co.Ltd
    • GSK Plc
    • Hawaii Biotech Inc
    • InvivoGen
    • LiteVax BV
    • Merck KGaA
    • Mukta Industries
    • NovavaxInc
    • OncovirInc
    • OZ Biosciences
    • Pacific GeneTech Limited
    • Phibro Animal Health Corporation
簡介目錄
Product Code: VMR112110210

The global vaccine adjuvants market size is expected to reach USD 7.09 Billion in 2034 from USD 4.30 Billion in 2025, growing at a CAGR of 5.72 during 2026-2034.The Global Vaccine Adjuvants market has recorded steady growth driven by rising vaccine research and development activities and increasing adoption of recombinant and subunit vaccines that require enhanced immune stimulation. Expanding immunization programs, coupled with greater preparedness for infectious disease outbreaks, have strengthened demand. Biopharmaceutical collaborations and public health funding initiatives are also accelerating innovation in novel adjuvant platforms, contributing to expanding commercial opportunities and sustained global market expansion.

Key drivers include the need to improve vaccine efficacy in elderly and immunocompromised populations, technological advancements in nanoparticle and toll-like receptor-based adjuvants, and increasing regulatory support for advanced vaccine formulations. Growing investments in pandemic preparedness and therapeutic vaccines further reinforce demand. Moreover, enhanced safety profiles and improved immune response durability are encouraging wider integration of adjuvants across both preventive and therapeutic vaccine pipelines.

Future prospects remain strong as manufacturers focus on combination adjuvants and precision-based immune modulation strategies. Expansion into oncology vaccines, personalized immunization platforms, and emerging markets will generate additional revenue streams. Advancements in large-scale manufacturing and improved understanding of immune mechanisms are expected to strengthen commercialization pathways, positioning the market for sustained long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Pathogen
  • Adjuvant Emulsion
  • Particulate
  • Combination
  • Others

By Application

  • Infectious Diseases
  • Cancer
  • Others

By Administration

  • Oral
  • Intradermal
  • Intranasal
  • Intramuscular
  • Others

COMPANIES PROFILED

  • Adjuvance Technologies Inc., Agenus Inc., Allergy Therapeutics plc, Aurorium, CaPtivate Pharmaceuticals LLC, Creative Diagnostics, Croda International Plc (Brenntag Biosector), CSL Limited, Dynavax Technologies Corporation, EuBiologics Co., Ltd., GSK plc, Hawaii Biotech Inc., InvivoGen, LiteVax B.V., Merck KGaA, Mukta Industries, Novavax, Inc., Oncovir, Inc., OZ Biosciences, Pacific GeneTech Limited, Phibro Animal Health Corporation

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VACCINE ADJUVANTS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Pathogen Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Adjuvant Emulsion Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Particulate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Combination Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VACCINE ADJUVANTS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VACCINE ADJUVANTS MARKET: BY ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Intradermal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VACCINE ADJUVANTS MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By Administration
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VACCINE ADJUVANTS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Adjuvance Technologies Inc
    • 9.2.2 Agenus Inc
    • 9.2.3 Allergy Therapeutics Plc
    • 9.2.4 Aurorium
    • 9.2.5 CaPtivate Pharmaceuticals LLC
    • 9.2.6 Creative Diagnostics
    • 9.2.7 Croda International Plc (Brenntag Biosector)
    • 9.2.8 CSL Limited
    • 9.2.9 Dynavax Technologies Corporation
    • 9.2.10 EuBiologics Co.Ltd
    • 9.2.11 GSK Plc
    • 9.2.12 Hawaii Biotech Inc
    • 9.2.13 InvivoGen
    • 9.2.14 LiteVax B.V
    • 9.2.15 Merck KGaA
    • 9.2.16 Mukta Industries
    • 9.2.17 NovavaxInc
    • 9.2.18 OncovirInc
    • 9.2.19 OZ Biosciences
    • 9.2.20 Pacific GeneTech Limited
    • 9.2.21 Phibro Animal Health Corporation